This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

6 Jul 2011

Almirall Strengthens Business in European Markets

With the introduction of two new products Almirall strengthens its international presence in Europe's largest pharmaceutical market.

Almirall, S.A. announces the launch, in Germany, of Sativex for the treatment of spasticity in multiple sclerosis and the approval of Actikerall for the treatment of hyperkeratotic actinic keratosis (grade I/II) in adult patients which will be launched on July 15th.


This represents a step forward for Almirall to reinforce its presence in European markets.


"Being a company based on innovation and committed to health, Almirall aims to provide innovative solutions for patients. With the launch of Sativex we provide a novel alternative to patients who suffer from spasticity in MS. Also, with the launch of Actikerall we will bring a new topical solution for non-melanoma skin cancer sufferers”, said Farid Taha, Managing Director, Almirall, Germany, Aus

Related News